Ann: Merger with CDA Health Pty Ltd, page-42

yes this is what I thought as well. Also if you forecast growth using current annual medicinal cannabis approvals of 90%pa -for sector growth (approx growth on prior year for 22 https://www.tga.gov.au/medicinal-cannabis-special-access-scheme-category-b-data) puts revenue of combined entity at approx $45m for 2022 (slightly higher growth for CAU portion of revenues). which means trading on forward multiple of 2X rev at current share price when the market average for cannabis companies is approximately 16X. Cronos Group the parent company is trading on 35X for similar growth.